1,597,827 Shares of Common Stock 9,000,000 Shares of Non-Voting Common Stock IGM Biosciences, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • June 23rd, 2023 • IGM Biosciences, Inc. • Pharmaceutical preparations • New York
IGM BIOSCIENCES, INC. INDEMNIFICATION AGREEMENTIndemnification Agreement • September 3rd, 2019 • IGM Biosciences, Inc. • Pharmaceutical preparations • Delaware
This Indemnification Agreement (this “Agreement”) is dated as of [________], 2019 and is between IGM Biosciences, Inc., a Delaware corporation (the “Company”), and [insert name of indemnitee] (“Indemnitee”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • December 7th, 2020 • IGM Biosciences, Inc. • Pharmaceutical preparations • New York
This Registration Rights Agreement (this “Agreement”) is made as of _________, 2020, by and between IGM BIOSCIENCES, INC., a Delaware corporation (the “Company”), and the persons listed on the attached Schedule A who are signatories to this Agreement (collectively, the “Investors”). Unless otherwise defined herein, capitalized terms used in this Agreement have the respective meanings ascribed to them in the Investor Rights Agreement (as defined below).
August 19, 2019 Mr. Misbah Tahir c/o IGM Biosciences, Inc. Mountain View, CA 94043 Dear Mr. Tahir:Letter Agreement • August 19th, 2019 • IGM Biosciences, Inc. • Pharmaceutical preparations
This letter agreement (the “Agreement”) is entered into between Misbah Tahir (“you”) and IGM Biosciences, Inc. (the “Company” or “we”), effective as of August 19, 2019 (the “Effective Date”), to confirm the terms and conditions of your employment with the Company as of the Effective Date. This Agreement supersedes and replaces any and all employment terms, compensation, or benefits you may have had or to which you may have been entitled prior to the Effective Date.
EMPLOYMENT AGREEMENTEmployment Agreement • August 9th, 2021 • IGM Biosciences, Inc. • Pharmaceutical preparations • California
This EMPLOYMENT AGREEMENT, dated as of July 29, 2021 is between IGM Biosciences, Inc., a Delaware corporation (the “Company”) and Chris H. Takimoto (“Executive”). In consideration of the mutual covenants contained herein, the parties agree as follows:
NOMINATING AGREEMENTNominating Agreement • August 19th, 2019 • IGM Biosciences, Inc. • Pharmaceutical preparations • Delaware
THIS NOMINATING AGREEMENT (this “Agreement”), dated as of June 28, 2019, is by and between IGM Biosciences, Inc., a Delaware corporation (the “Company”) Redmile Biopharma Investments II, L.P., RAF, L.P. and Redmile Strategic Master Fund, LP (each an “Investor” and together, the “Investors”).
NOMINATING AGREEMENTNominating Agreement • August 19th, 2019 • IGM Biosciences, Inc. • Pharmaceutical preparations • Delaware
THIS NOMINATING AGREEMENT (this “Agreement”), dated as of June 28, 2019, is by and between IGM Biosciences, Inc., a Delaware corporation (the “Company”) 667, L.P. and Baker Brothers Life Sciences, L.P. (each an “Investor” and together, the “Investors”).
NOMINATING AGREEMENTNominating Agreement • August 19th, 2019 • IGM Biosciences, Inc. • Pharmaceutical preparations • Delaware
THIS NOMINATING AGREEMENT (this “Agreement”), dated as of June 28, 2019, is by and between IGM Biosciences, Inc., a Delaware corporation (the “Company”) and Haldor Topsøe Holding A/S (the “Investor”).
RESTRICTED STOCK GRANT AGREEMENTRestricted Stock Grant Agreement • August 19th, 2019 • IGM Biosciences, Inc. • Pharmaceutical preparations • California
THIS AGREEMENT is made as of the 30th day of December, 2018, by and between IGM Biosciences, Inc., a Delaware corporation (the “Company”), and Daniel S. Chen, MD, PhD (the “Grantee”).
EMPLOYMENT AGREEMENTEmployment Agreement • August 19th, 2019 • IGM Biosciences, Inc. • Pharmaceutical preparations • California
This EMPLOYMENT AGREEMENT, dated as of July 12, 2018 is between IGM Biosciences, Inc., a Delaware corporation (the “Company”) and Daniel S. Chen, M.D., Ph.D. (“Executive”). In consideration of the mutual covenants contained herein, the parties agree as follows:
COMMON STOCK PURCHASE AGREEMENTCommon Stock Purchase Agreement • June 23rd, 2023 • IGM Biosciences, Inc. • Pharmaceutical preparations • Delaware
This COMMON STOCK PURCHASE AGREEMENT (the “Agreement”), dated as of June 22, 2023, is entered into by and between IGM Biosciences, Inc., a Delaware corporation (the “Company”), and the buyers listed on the Schedule of Buyers attached hereto as Exhibit A, as may be updated in accordance with Section 9(g) (individually, together with its permitted designees and assigns, the “Buyer” and collectively, the “Buyers”). Capitalized terms used herein are defined in-line or in Section 7 hereof.
AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENTInvestor Rights Agreement • August 9th, 2019 • IGM Biosciences, Inc. • Pharmaceutical preparations • Delaware
THIS AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT is made and entered into as of June 28, 2019, by and between IGM BIOSCIENCES, INC., a Delaware corporation (the “Corporation”), and the undersigned holders of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock of the Corporation (the “Investors”).
FIRST AMENDMENT TO LEASELease • July 13th, 2021 • IGM Biosciences, Inc. • Pharmaceutical preparations
This First Amendment to Lease (“First Amendment”), effective as of July 1, 2021, is entered into by and between Real Property Investments, LLC, a Colorado limited liability company (“Landlord”), and IGM Biosciences, Inc., a Delaware corporation (“Tenant”). Any capitalized terms that are used in this First Amendment but not defined herein shall have the meaning given to them in the Lease (defined below).
COLLABORATION AND LICENSE AGREEMENT by and between IGM BIOSCIENCES, INC. and GENZYME CORPORATION dated as of March 28, 2022Collaboration and License Agreement • March 29th, 2022 • IGM Biosciences, Inc. • Pharmaceutical preparations
This COLLABORATION AND LICENSE AGREEMENT (this “Agreement”) is entered into as of March 28, 2022 (the “Execution Date”) by and between IGM Biosciences, Inc., a corporation organized and existing under the laws of Delaware (“IGM”) and Genzyme Corporation, a corporation organized under the laws of Massachusetts, with its principal business address at 450 Water St, Cambridge, MA 02141 (“Sanofi”). IGM and Sanofi are each referred to herein by name or as a “Party” or, collectively, as the “Parties.”
